Funder
Quebec Ministry of Health and Social Services
Subject
Public Health, Environmental and Occupational Health,Health Informatics
Reference36 articles.
1. Abbvie inc. SYNAGIS® palivizumab Product Monograph [En ligne]. https://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/SYNAGIS_PM_EN.pdf.
2. Diagnostic yield and clinical impact of routine cell culture for respiratory viruses among children with a negative multiplex RT-PCR result;AlGhounaim;J. Clin. Virol. Off. Publ. Pan. Am. Soc. Clin. Virol.,2017
3. American Academy of Pediatrics Committee on Infectious Diseases, 2014. American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 134(2), e620–638.
4. Andabaka, T., Nickerson, J.W., Rojas-Reyes, M.X., Rueda, J.D., Bacic Vrca, V., Barsic, B., 2013. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst. Rev. (4), CD006602.
5. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis;Anderson;Pediatr. Infect. Dis. J.,2017
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献